Skip to content

Safety observation and comfort exploration of Iomeprol 300 in clinical application

Safety observation and comfort exploration of Iomeprol 300 in clinical application

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300070917
Enrollment
Unknown
Registered
2023-04-26
Start date
2023-04-30
Completion date
Unknown
Last updated
2023-06-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CT Contrast-enhanced

Interventions

Case series:iomeprol

Sponsors

Leshan People 's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1 ) Patients who planned to use iodine contrast agent for CT enhanced angiography ; 2 ) Complete clinical data ; 3 ) Consciousness, hearing impairment, clear language expression, able to cooperate with the examination ; 4 ) no respiratory failure, allergic asthma ; serious diseases without vital organs ; 5 ) no serious thyroid dysfunction, edema, drug allergy history and other imaging related contraindications ; 6 ) no mental illness, cerebrovascular disease ; 7 ) Patients who voluntarily joined the study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1 ) Patients with a history of allergic reactions to iodine contrast agents ; 2 ) patients with organic critical lesions ; 3 ) Patients with liver and kidney dysfunction ; 4 ) CT scan contraindications ; 5 ) pregnant and lactating women ; 6 ) participate in other drug clinical researchers within 30 days ; ( 7 ) The investigator determines any precarious or potentially precarious status of the subject 's safety and compliance with the study ; it can cause the subjects to fail to follow the research plan and even endanger the safety of patients with complications or social environment.

Design outcomes

Primary

MeasureTime frame
Adverse events;

Secondary

MeasureTime frame
comfort evaluation;

Countries

China

Contacts

Public ContactXiao Zhang

Leshan People 's Hospital

zhangxiao_ls@163.com+86 18981386136

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026